SUN PHARMACEUTICAL IND L Latest Share Price (SUNPHARMA)
TODAY IN ONE LINE
SUNPHARMA slipped 0.9% on light volume, in line with Nifty's 0.1% move, supported by recent strong earnings.
With a market cap of ₹4.56 L Cr., it trades at a P/E of 38.35. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
SUN PHARMACEUTICAL IND L flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 25.6% YoY
- ●Consistent GrowthEPS compounded at 10.6% over 3 years
- ●Quarterly OutperformanceLatest quarter Sales up 166.5% and Profit up 160.2%
- ●Healthy Operating MarginsOPM is structurally strong at 22.8%
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●FII SellingFII holding decreased by 1.40% QoQ
- ●Rising Receivables vs SalesReceivables grew 12.9% outpacing sales growth of 8.4%
Latest SUN PHARMACEUTICAL IND L News
What changed recently?
Recent events, corporate actions, and announcements.
SUN PHARMACEUTICAL IND L valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for SUN PHARMACEUTICAL IND L, framed against the sector median so the premium or discount is obvious at a glance.
SUN PHARMACEUTICAL IND L trades at a P/E of 38.35× and P/B of 5.55×, against the Healthcare sector median P/E of 41.28×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
SUN PHARMACEUTICAL IND L technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for SUN PHARMACEUTICAL IND L — derived from the latest tape, not yesterday's close.
SUN PHARMACEUTICAL IND L last traded at ₹1,899 with an intraday range of ₹1,895–₹1,917.3 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1899.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1957.13 | +58.13 | +3.06% |
| R3 | 1934.83 | +35.83 | +1.89% |
| R2 | 1926.07 | +27.07 | +1.43% |
| R1 | 1912.53 | +13.53 | +0.71% |
| PIVOT | 1903.77 | 4.77 | 0.25% |
| CURRENT | 1899.00 | — | — |
| S1 | 1890.23 | -8.77 | -0.46% |
| S2 | 1881.47 | -17.53 | -0.92% |
| S3 | 1867.93 | -31.07 | -1.64% |
| S4 | 1845.63 | -53.37 | -2.81% |
SUNPHARMA is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹1906–₹1917.3
Trading Below opening range, showing Bearishness
SUN PHARMACEUTICAL IND L financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for SUN PHARMACEUTICAL IND L — consolidated or standalone — with margins, YoY growth and key ratios inline.
SUN PHARMACEUTICAL IND L reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹4.56 L Cr. and reported EPS of ₹50.42.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 52,578 | 58,462 ▲ 11.2% |
| Sales Growth YoY %Derived | 8.42% | 11.19% |
| Other Income | 1,965 | 1,972 ▲ 0.3% |
| Total Income | 54,543 | 60,434 ▲ 10.8% |
| 10,747 | 11,544 ▲ 7.4% | |
| Gross ProfitDerived | 41,831 | 46,918 ▲ 12.2% |
| Gross Margin %Derived | 79.56% | 80.25% |
| 26,559 | 29,187 ▲ 9.9% | |
| EBITDA (Operating Profit)Derived | 15,272 | 17,731 ▲ 16.1% |
| OPM %Derived | 29.05% | 30.33% |
| 2,129 | 1,969 ▼ 7.5% | |
| Profit Before Tax (PBT) | 13,752 | 15,119 ▲ 9.9% |
| 2,772 | 3,554 ▲ 28.2% | |
| Effective Tax %Derived | 20.16% | 23.51% |
| Total Profit for Period | 10,965 | 11,509 ▲ 5.0% |
| Less: Non-controlling Interests | 36 | 29 ▼ 18.1% |
| Net Profit (Owner's PAT)Derived | 10,929 | 11,479 ▲ 5.0% |
| Net Profit Margin %Derived | 20.79% | 19.64% |
| PAT Growth YoY %Derived | 14.12% | 5.04% |
| Earnings Per Share (EPS ₹) | 45.55 | 47.84 ▲ 5.0% |
| Diluted Shares Outstanding (Cr) | 240 | 240 ▲ 0.0% |
| Share of Profit from Associates/JVs | -15 | -56 ▼ 264.0% |
| Other Comprehensive Income (Net of Tax) | 912 | 3,827 ▲ 319.4% |
| Total Expenses (incl. D&A & Interest) | 40,791 | 45,315 ▲ 11.1% |
| Material Cost % of RevenueDerived | 12.27% | 12.64% |
| Employee Cost % of RevenueDerived | 18.97% | 19.53% |
| Other Cost % of RevenueDerived | 31.55% | 30.39% |
| Interest Coverage (x)Derived | 54.88x | 43.65x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 26,489 | 29,066 ▲ 9.7% | 32,838 ▲ 13.0% | 33,498 ▲ 2.0% | 38,654 ▲ 15.4% | 43,886 ▲ 13.5% | 48,497 ▲ 10.5% | 52,578 ▲ 8.4% | 58,462 ▲ 11.2% | |
| Sales Growth YoY %Derived | — | 9.73% | 12.98% | 2.01% | 15.39% | 13.53% | 10.51% | 8.42% | 11.19% | |
| Other Income | 839 | 1,025 ▲ 22.3% | 636 ▼ 38.0% | 836 ▲ 31.4% | 922 ▲ 10.3% | 635 ▼ 31.1% | 1,354 ▲ 113.4% | 1,965 ▲ 45.1% | 1,972 ▲ 0.3% | |
| Total Income | 27,328 | 30,091 ▲ 10.1% | 33,473 ▲ 11.2% | 34,334 ▲ 2.6% | 39,576 ▲ 15.3% | 44,520 ▲ 12.5% | 49,851 ▲ 12.0% | 54,543 ▲ 9.4% | 60,434 ▲ 10.8% | |
7,425 | 7,869 ▲ 6.0% | 9,230 ▲ 17.3% | 8,690 ▼ 5.9% | 10,352 ▲ 19.1% | 10,662 ▲ 3.0% | 10,663 ▲ 0.0% | 10,747 ▲ 0.8% | 11,544 ▲ 7.4% | ||
| Gross ProfitDerived | 19,065 | 21,197 ▲ 11.2% | 23,607 ▲ 11.4% | 24,808 ▲ 5.1% | 28,303 ▲ 14.1% | 33,224 ▲ 17.4% | 37,834 ▲ 13.9% | 41,831 ▲ 10.6% | 46,918 ▲ 12.2% | |
| Gross Margin %Derived | 71.97% | 72.93% | 71.89% | 74.06% | 73.22% | 75.70% | 78.01% | 79.56% | 80.25% | |
13,457 | 14,889 ▲ 10.6% | 16,617 ▲ 11.6% | 16,317 ▼ 1.8% | 17,905 ▲ 9.7% | 21,577 ▲ 20.5% | 24,811 ▲ 15.0% | 26,559 ▲ 7.0% | 29,187 ▲ 9.9% | ||
| EBITDA (Operating Profit)Derived | 5,608 | 6,308 ▲ 12.5% | 6,990 ▲ 10.8% | 8,491 ▲ 21.5% | 10,398 ▲ 22.5% | 11,647 ▲ 12.0% | 13,023 ▲ 11.8% | 15,272 ▲ 17.3% | 17,731 ▲ 16.1% | |
| OPM %Derived | 21.17% | 21.70% | 21.29% | 25.35% | 26.90% | 26.54% | 26.85% | 29.05% | 30.33% | |
1,067 | 1,094 ▲ 2.6% | 2,095 ▲ 91.5% | -2,085 ▼ 199.5% | -2,296 ▼ 10.1% | 2,530 ▲ 210.2% | 2,301 ▼ 9.1% | 2,129 ▼ 7.5% | 1,969 ▼ 7.5% | ||
| Profit Before Tax (PBT) | 3,479 | 3,810 ▲ 9.5% | 5,010 ▲ 31.5% | 2,799 ▼ 44.1% | 4,481 ▲ 60.1% | 9,408 ▲ 109.9% | 11,088 ▲ 17.9% | 13,752 ▲ 24.0% | 15,119 ▲ 9.9% | |
845 | 601 ▼ 28.9% | 823 ▲ 36.9% | 515 ▼ 37.4% | 1,076 ▲ 109.0% | 848 ▼ 21.2% | 1,439 ▲ 69.8% | 2,772 ▲ 92.6% | 3,554 ▲ 28.2% | ||
| Effective Tax %Derived | 24.29% | 15.77% | 16.42% | 18.39% | 24.00% | 9.01% | 12.98% | 20.16% | 23.51% | |
| Total Profit for Period | 2,608 | 3,208 ▲ 23.0% | 4,172 ▲ 30.1% | 2,272 ▼ 45.5% | 3,389 ▲ 49.2% | 8,513 ▲ 151.2% | 9,610 ▲ 12.9% | 10,965 ▲ 14.1% | 11,509 ▲ 5.0% | |
| Less: Non-controlling Interests | 447 | 542 ▲ 21.4% | 407 ▼ 25.0% | -631 ▼ 255.1% | 117 ▲ 118.5% | 39 ▼ 66.2% | 34 ▼ 14.5% | 36 ▲ 6.1% | 29 ▼ 18.1% | |
| Net Profit (Owner's PAT)Derived | 2,162 | 2,665 ▲ 23.3% | 3,765 ▲ 41.3% | 2,904 ▼ 22.9% | 3,273 ▲ 12.7% | 8,474 ▲ 158.9% | 9,576 ▲ 13.0% | 10,929 ▲ 14.1% | 11,479 ▲ 5.0% | |
| Net Profit Margin %Derived | 8.16% | 9.17% | 11.47% | 8.67% | 8.47% | 19.31% | 19.75% | 20.79% | 19.64% | |
| PAT Growth YoY %Derived | — | 23.31% | 41.25% | -22.87% | 12.70% | 158.91% | 13.01% | 14.12% | 5.04% | |
| Earnings Per Share (EPS ₹) | 9.01 | 11.11 ▲ 23.3% | 15.69 ▲ 41.2% | 12.10 ▼ 22.9% | 13.64 ▲ 12.7% | 35.32 ▲ 158.9% | 39.91 ▲ 13.0% | 45.55 ▲ 14.1% | 47.84 ▲ 5.0% | |
| Diluted Shares Outstanding (Cr) | 240 | 240 ▲ 0.0% | 240 ▲ 0.0% | 240 ▲ 0.0% | 240 ▲ 0.0% | 240 ▲ 0.0% | 240 ▲ 0.0% | 240 ▲ 0.0% | 240 ▲ 0.0% | |
| Share of Profit from Associates/JVs | -25 | -1 ▲ 94.3% | -15 ▼ 915.8% | -12 ▲ 16.9% | -17 ▼ 34.1% | -48 ▼ 189.6% | -38 ▲ 19.8% | -15 ▲ 60.0% | -56 ▼ 264.0% | |
| Other Comprehensive Income (Net of Tax) | 523 | 1,680 ▲ 221.1% | 2,121 ▲ 26.2% | -146 ▼ 106.9% | 557 ▲ 481.6% | 2,257 ▲ 305.0% | 1,142 ▼ 49.4% | 912 ▼ 20.1% | 3,827 ▲ 319.4% | |
| Total Expenses (incl. D&A & Interest) | 23,849 | 26,281 ▲ 10.2% | 28,464 ▲ 8.3% | 31,534 ▲ 10.8% | 35,095 ▲ 11.3% | 35,112 ▲ 0.0% | 38,763 ▲ 10.4% | 40,791 ▲ 5.2% | 45,315 ▲ 11.1% | |
| Material Cost % of RevenueDerived | 16.85% | 19.90% | 16.80% | 18.37% | 18.24% | 17.72% | 14.24% | 12.27% | 12.64% | |
| Employee Cost % of RevenueDerived | 20.26% | 20.53% | 19.38% | 20.49% | 18.89% | 18.90% | 19.44% | 18.97% | 19.53% | |
| Other Cost % of RevenueDerived | 30.54% | 30.70% | 31.23% | 28.22% | 27.43% | 30.26% | 31.72% | 31.55% | 30.39% | |
| Interest Coverage (x)Derived | 7.94x | 8.20x | 16.31x | 45.33x | 64.81x | 53.01x | 43.89x | 54.88x | 43.65x |
SUN PHARMACEUTICAL IND L segment analysis : revenue and profit mix.
Disclosed business segments at SUN PHARMACEUTICAL IND L with their share of revenue and profit, switchable between consolidated and standalone reporting.
SUN PHARMACEUTICAL IND L discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for SUN PHARMACEUTICAL IND L.
Our AI distills the core fundamental drivers supporting SUN PHARMACEUTICAL IND L, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
SUN PHARMACEUTICAL IND L's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Operating margin 23.28% substantially outpaces pharmaceutical sector peers significantly
ROCE 20.50% and ROE 16.00% demonstrate efficient capital deployment consistently
Low debt-to-equity 0.0060x ensures financial flexibility and fortress balance sheet
TTM EPS grew 25.6% YoY, demonstrating strong earnings momentum and profitability
Market cap ₹4.56 LCr establishes dominant scale in Indian generic pharmaceutical industry
Key Risks.
P/E 39.03x substantially exceeds peer median, suggesting premium valuation risk
Dividend yield 0.83% may disappoint income-focused investors seeking higher returns
Latest quarterly EPS grew 26.2% YoY yet PAT rose only 5.95%, signaling earnings volatility
Stock price near 52-week high ₹2,046.90, limiting near-term upside potential
Net profit margin 18.56% TTM declined from historical levels, indicating margin compression
Flip Conditions.
Valuation risk. a P/E above 50 (~1.2× the sector multiple of 41.3) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.10. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
SUN PHARMACEUTICAL IND L peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — SUN PHARMACEUTICAL IND L is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
SUN PHARMACEUTICAL IND L chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for SUN PHARMACEUTICAL IND L — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
SUN PHARMACEUTICAL IND L delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for SUN PHARMACEUTICAL IND L over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in SUN PHARMACEUTICAL IND L stood at 65.1% of traded volume, against a 20-day average of 64.2%.
SUN PHARMACEUTICAL IND L announcements: results, concalls, ratings, M&A.
Filings SUN PHARMACEUTICAL IND L sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
SUN PHARMACEUTICAL IND L files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 174 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Sun Pharmaceutical Industries Limited has informed the Exchange about Schedule of meet
Press Release
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated September 01, 2026, titled "Sun Pharma Participates…
Copy of Newspaper Publication
Newspaper advertisements about Postal Ballot/E-Voting
Analysts/Institutional Investor Meet/Con. Call Updates
Sun Pharmaceutical Industries Limited has informed the Exchange about Schedule of meet
Investor decks & rating reports.
SUN PHARMACEUTICAL IND L dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue SUN PHARMACEUTICAL IND L has declared, sequenced by announce and record date.
SUN PHARMACEUTICAL IND L corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About SUN PHARMACEUTICAL IND L: business, sector, key facts.
What SUN PHARMACEUTICAL IND L does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
SUN PHARMACEUTICAL IND L operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: SUNPHARMA, BSE: 524715.
Sun Pharmaceutical Industries Limited (Sun Pharma) is a global pharmaceutical company headquartered in Mumbai, India. Established in 1983, the company operates across the entire pharmaceutical value chain, encompassing research and development, manufacturing, and marketing of a diverse portfolio of pharmaceutical products.
Sun Pharma's core business revolves around the development, manufacturing, and marketing of both branded and generic formulations. Their product portfolio spans a wide range of therapeutic areas, including but not limited to central nervous system treatments, dermatological products, cardiovascular medications, oncology drugs, and treatments for neuropsychiatric, gastroenterological, and infectious diseases. They also cater to various other therapeutic segments such as diabetology, pain management, respiratory ailments, and women's health.
A significant aspect of Sun Pharma's operations is the production of Active Pharmaceutical Ingredients (APIs). These APIs are the fundamental building blocks of many medications and Sun Pharma manufactures a substantial range, including those used in anti-cancer therapies, peptide-based drugs, steroids, hormones, and immunosuppressants. This vertical integration allows for greater control over the supply chain and cost-effectiveness.
The company offers its formulations in various forms, including tablets, capsules, injectables, inhalers, topical applications (ointments and creams), and liquids. Beyond generic medications, Sun Pharma also markets specialty medications and antiretroviral drugs, along with over-the-counter (OTC) products. This diversification helps cater to a broad spectrum of patient needs and market segments.
In essence, Sun Pharma's business model is built upon a foundation of comprehensive pharmaceutical capabilities, covering the entire spectrum from API manufacturing to the marketing of finished dosage forms across various therapeutic categories. Their global presence and diversified product portfolio position them as a major player in the worldwide pharmaceutical industry.
Go deeper on SUN PHARMACEUTICAL IND L
- SUN PHARMACEUTICAL IND L resultsQuarter-by-quarter revenue, profit, EPS and margins for SUN PHARMACEUTICAL IND L.
- SUN PHARMACEUTICAL IND L dividendEvery dividend SUN PHARMACEUTICAL IND L has declared, with ex-dates and yield.
- SUN PHARMACEUTICAL IND L shareholdingPromoter, FII and DII holding in SUN PHARMACEUTICAL IND L, quarter by quarter.
- SUN PHARMACEUTICAL IND L financialsSUN PHARMACEUTICAL IND L profit & loss, balance sheet and cash flow by year.
- SUN PHARMACEUTICAL IND L technical analysisPivots, CPR and live indicator readings for SUN PHARMACEUTICAL IND L.
- SUN PHARMACEUTICAL IND L corporate actionsBonus issues, splits, rights and buybacks declared by SUN PHARMACEUTICAL IND L.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about SUN PHARMACEUTICAL IND L (SUNPHARMA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of SUN PHARMACEUTICAL IND L (SUNPHARMA)?
The current share price of SUN PHARMACEUTICAL IND L (SUNPHARMA) is ₹1,899.00. Today, the stock has declined by ₹17.00 (0.89%), trading in a range of ₹1,895.00 to ₹1,917.30. The stock opened at ₹1,912.00 with a trading volume of 7,61,333 shares.
02Is SUN PHARMACEUTICAL IND L stock a good investment for long-term?
SUN PHARMACEUTICAL IND L can be considered for long-term investment based on several factors. The company has a market capitalization of ₹4.56 L Cr., P/E ratio of 38.35, ROE of 11.76%, and ROCE of 9.6%. The dividend yield stands at 0.83%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of SUN PHARMACEUTICAL IND L stock?
The 52-week high price of SUN PHARMACEUTICAL IND L (SUNPHARMA) is ₹2,046.90, while the 52-week low is ₹1,548.00. Currently trading at ₹1,899.00, the stock is 22.67% above its 52-week low and 7.23% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy SUN PHARMACEUTICAL IND L stock at the current price?
Whether to buy SUN PHARMACEUTICAL IND L stock at ₹1,899.00 depends on multiple factors. The stock is currently trading with a P/E ratio of 38.35 and P/B ratio of 5.55. Today's performance shows a loss of 0.89%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of SUN PHARMACEUTICAL IND L and when is the next dividend?
SUN PHARMACEUTICAL IND L offers a dividend yield of 0.83%, which means for every ₹100 invested at the current price of ₹1,899.00, you can expect to receive approximately ₹0.83 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of SUN PHARMACEUTICAL IND L?
SUN PHARMACEUTICAL IND L's key financial metrics include: P/E Ratio: 38.35, P/B Ratio: 5.55, ROE: 11.76%, ROCE: 9.6%, Dividend Yield: 0.83%, EPS: ₹50.42, Book Value: ₹348.31, and Debt-to-Equity: 0.6. The company's market cap stands at ₹4.56 L Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is SUN PHARMACEUTICAL IND L stock performing today in the market?
SUN PHARMACEUTICAL IND L stock opened at ₹1,912.00 and is currently trading at ₹1,899.00, showing a decline of ₹17.00 (0.89%). The intraday high is ₹1,917.30 and low is ₹1,895.00. The trading volume stands at 7,61,333 shares, indicating moderate market participation today.
08What is the P/E ratio of SUN PHARMACEUTICAL IND L and what does it indicate?
SUN PHARMACEUTICAL IND L has a Price-to-Earnings (P/E) ratio of 38.35, which means investors are willing to pay 38.35 for every ₹1 of earnings. With an EPS of ₹50.42, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about SUN PHARMACEUTICAL IND L (SUNPHARMA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.